p53 determination alongside classical prognostic factors in node- negative breast cancer: An evaluation at more than 10-year follow-up

Annals of Oncology

Volumn 11, Issue 4, 2000, Pages 393-397

  Ferrero, J M ^a   Ramaioli, A ^a   Formento, J L ^a   Francoual, M ^a   Etienne, M C ^a   Peyrottes, I ^a   Ettore, F ^a   Leblanc Talent, P ^a   Namer, M ^a   Milano, G ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Breast cancer; p53; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0034029990     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008359722254     Document Type: Article

References (34)

1. Dexter DL, Kowalski HM, Blazar BA et al. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 1978; 38: 3174-81.
2. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-19.
3. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-8.
4. Spyratos F, Martin PM, Hacène K et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266-72.
5. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochem Biophys Acta 1996; 1287: 77-102.
6. Levesque MA, Yu He, Clark GM, Diamandis EP. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: A prognostic factor in a large breast cancer cohort. J Clin Oncol 1998; 16: 2641-50.
7. Rimer BK, Schildkraut J. Cancer screening. In De Vita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott-Raven 1997; 619-32.
8. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77.
9. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
10. Scarff RW, Torloni H. Histological Typing of Breast Tumors. Geneva: World Health Organization 1968; 13-20.
11. Romain S, Formento JL, Guirou O et al. Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences. Eur J Cancer 1994; 30: 740-6.
12. Sjogren S, Inganas M, Norberg T et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173-82.
13. Falette N, Paperin MP, Treilleux I et al. Prognostic value of p53 gene mutations in a large of node-negative breast cancer patients. Cancer Res 1998; 58: 1451-5.
14. Iacopetta B, Grieu F, Powell B et al. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 1998; 4: 1597-602.
15. Silvestrini R, Rao S, Benini E et al. Immunohistochemical detection of p53 in clinical breast cancers: A look at methodologic approaches. J Natl Cancer Inst 1995; 87: 1020.
16. Borg A, Lennerstrand J, Stenmark-Askmalm M et al. Prognostic significance of p53 overexpression in primary breast cancer. A novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 1995; 71: 1013-7.
17. de Witte HH, Foekens JA, Lennerstrand J et al. Prognostic significance of TP53 accumulation in human primary breast cancer. Comparison between a rapid quantitative immunoassay and SSCP analysis. Int J Cancer 1996; 69: 125-30.
18. Berns EM, De Witte HH, Klijn JG et al. Prognostic value of TP53 protein accumulation in human primary breast cancer: An analysis by luminometric immunoassay on 1491 tumor cytosols. Anticancer Res 1997; 17: 3003-6.
19. Allred DC, Clark GM, Elledge R et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
20. Silvestrini R, Daidone MG, Benini E et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996; 2: 2007-13.
21. Bombardieri E, Seregni E, Daidone MG et al. p53 accumulation in primary breast cancer: A comparison between immunohistochemistry and a novel luminometric immunoassay. Tumour Biol 1998; 19: 12-8.
22. Soong R, Iacopetta BJ, Harvey JM et al. Detection of p53 gene mutation by rapid PCR-SSCP and its assocation with poor survival in breast cancer. Int J Cancer 1997; 74: 642-7.
23. Sasa M, Kondo K, Komadi K et al. p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer. J Surg Oncol 1994; 56: 46-50.
24. Seshadri R, Leong AS, McCaul K et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. Int J Cancer 1996; 69: 135-41.
25. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B. p53 as a prognostic factor in stage 1 breast cancer. South-East Sweden Breast Cancer Group. Br J Cancer 1995; 72: 715-9.
26. Umekita Y, Kobayashi K, Yoshida H. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. J Cancer Res 1994; 85: 825-30.
27. Bianchi S, Calzolari A, Vezzosi V et al. Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori 1997; 83: 669-72.
28. Thor AD, Moore DH, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
29. Elledge RM, Fuqua SAW, Clark GM et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993; 26: 225-35.
30. Silvestrini R, Benini E. Daidone MG et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-70.
31. Silvestrini R, Veneroni S, Daidone MG et al. The BCL-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
32. Isola J, Visakorpi T, Holli K, Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109-14.
33. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
34. Aas T, Borresen AL, Geisler S et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-4.